The benefits of construction digital twins, such as improved planning and design, streamlined collaboration, and effective risk management, are transforming how projects are executed. Photo via Getty Images

The construction industry is no stranger to embracing technological advancements, and one of the latest breakthroughs is the advent of construction digital twin technology.

Blending the virtual and physical worlds, construction digital twins offer immense potential for enhancing efficiency, reducing costs, and improving decision-making in construction projects.

It is a fascinating and ever-changing world of technology in construction digital twin technology and the following information explores its key components, benefits, and real-world applications in the construction sector.

What is a construction digital twin?

A construction digital twin is a virtual replica of a physical asset, process, or system that integrates real-time data from various sources to provide a holistic and dynamic representation. It encompasses a portion of the entire lifecycle of the project, potentially starting from planning and design into construction, commissioning, and data collection for ongoing maintenance.

The key components of a construction digital twin include the physical asset, sensors, data acquisition systems, connectivity infrastructure, cloud platforms, and advanced analytics. Various tools or platforms can be used at different stages of a project.

Skanska, a construction and development company, has created an internal hybrid approach combining a digital twin model with a custom analytics dashboard. The process allows for tracking production control during construction. What is used is a less-is-more approach to manual data entry into models and link to automated external data sources, which are combined and analyzed together in a separate dashboard. These color-coded models are combined with external data for schedule, cost, and man hour data for predictive analysis and production rates.

Improved planning and design

Digital twins allow design and construction professionals to simulate and optimize designs with a virtual model of the building before physically implementing them. This capability enables early detection and resolution of design flaws, reducing rework and costly delays. Adjacent building and city data can inform early design decisions. By leveraging the existing data from a digital twin, renovation projects can streamline processes, reduce risks, improve efficiency, and make informed design decisions, ultimately resulting in more successful and cost-effective renovations.

Enhanced construction processes

A construction digital twin allows stakeholders to visualize and simulate the project, analyze potential issues, optimize workflows, and make informed decisions. Key data sources include: installation, schedule, man hours, and cost. Additional real-time data from sensors embedded in physical assets can be fed into construction digital twins, enabling real-time monitoring and analysis. Project teams can enhance collaboration, improve efficiency, maintain schedule, reduce costs, and minimize risks throughout the construction process.

Effective risk management

Digital twins enable construction companies to simulate and analyze potential risks, such as structural weaknesses and environmental or safety hazards. Builders and their clients are at an advantage since they can address these risks in the virtual environment and significantly reduce the occurrence of accidents and associated liabilities.

Streamlined collaboration

Construction digital twins act as a shared platform for all stakeholders involved in a construction project, including architects, engineers, contractors, and facility managers. This flow of information fosters seamless collaboration, improves communication, and results in better decision-making through a data-driven environment. Solutions vary per stage and parties involved.

Real-world applications

Construction digital twin technology is already finding practical application in the construction industry, including locally at 1550 on The Green, Skanska’s state-of-the art, sustainable office building bringing the outdoors in.

Smart building construction

By creating a digital twin of a smart building, companies can optimize energy efficiency, HVAC systems, and space. The real-time monitoring of energy consumption and occupancy patterns combined with as-built BIM and systems data allows for predictive maintenance. Automations and AI assisted controls are also on the horizon.

Bringing it all together

Construction digital twin technology is poised to revolutionize the construction industry. By merging the virtual and physical realms, it enables construction professionals to make more informed decisions, enhance efficiency, and minimize risks.

The benefits of construction digital twins, such as improved planning and design, streamlined collaboration, and effective risk management, are transforming how projects are executed. As this technology continues to evolve, there are bound to be greater advancements in construction practices, ultimately leading to safer, smarter, and more sustainable built environments. Key data points and use cases vary per phase and stakeholder, and digital twins are a great asset throughout the project lifecycle.

------

Edwin Bailey is senior preconstruction technologist at Skanska, a leading multi-national project development and construction group, in Houston.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”